Furthermore, the gene expression patterns signaling metabolic reprogramming in SETD2 deficient ccRCC from lipid accumulation or glycolysis to oxidative phosphorylation or fatty acid beta oxidation are reversed through pharmacologic inhibition or genetic depletion of METTL3 in SETD2 KO 786-O cells (but not SETD2 proficient cells). Here, METTL3 is linked to nonpapillary renal cell carcinoma.